{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:56:08Z","timestamp":1793321768874,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:00:00Z","timestamp":1476921600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s12020-016-1146-8","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T08:20:18Z","timestamp":1476951618000},"page":"603-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Glucocorticoid-induced osteoporosis: pathophysiological role of GH\/IGF-I and PTH\/VITAMIN D axes, treatment options and guidelines"],"prefix":"10.1007","volume":"54","author":[{"given":"Gherardo","family":"Mazziotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Formenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Sbardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,20]]},"reference":[{"key":"1146_CR1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"E. Canalis, G. Mazziotti, A. Giustina, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319\u20131328 (2007)","journal-title":"Osteoporos. Int."},{"key":"1146_CR2","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1210\/jcem.86.12.8066","volume":"86","author":"A Canalis","year":"2001","unstructured":"A. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: summary of a workshop. J. Clin. Endocrinol. Metab. 86, 5681\u20135685 (2001)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-005-4918-2","volume":"7","author":"T Mancini","year":"2005","unstructured":"T. Mancini, M. Doga, G. Mazziotti, A. Giustina, Cushing\u2019s syndrome and bone. Pituitary 7, 1\u20134 (2005)","journal-title":"Pituitary"},{"key":"1146_CR4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000443866","volume":"46","author":"G Mazziotti G","year":"2016","unstructured":"G. Mazziotti G, A. Delgado, F. Maffezzoni, A. Formenti, A. Giustina, Skeletal fragility in endogenous hypercortisolism. Front. Horm. Res. 46, 66\u201373 (2016)","journal-title":"Front. Horm. Res."},{"key":"1146_CR5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/eje.0.1460051","volume":"146","author":"P Vestergaard","year":"2002","unstructured":"P. Vestergaard, J. Lindholm, J.O. J\u00f8rgensen, C. Hagen, H.C. Hoeck, P. Laurberg, L. Rejnmark, K. Brixen, L.O. Kristensen, U. Feldt-Rasmussen, L. Mosekilde, Increased risk of osteoporotic fractures in patients with Cushing\u2019s syndrome. Eur. J. Endocrinol. 146, 51\u201356 (2002)","journal-title":"Eur. J. Endocrinol."},{"key":"1146_CR6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00198-013-2588-y","volume":"25","author":"A Scillitani","year":"2015","unstructured":"A. Scillitani, G. Mazziotti, C. Di Somma, S. Moretti, A. Stigliano, R. Pivonello, A. Giustina, A. Colao; ABC group, treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos. Int. 25, 441\u2013446 (2015)","journal-title":"Osteoporos. Int."},{"key":"1146_CR7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","volume":"17","author":"G Mazziotti","year":"2006","unstructured":"G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144\u2013149 (2006)","journal-title":"Trends Endocrinol. Metab."},{"key":"1146_CR8","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1359\/JBMR.051103","volume":"21","author":"NE Lane","year":"2006","unstructured":"N.E. Lane, W. Yao, M. Balooch, R.K. Nalla, G. Balooch, S. Habelitz, J.H. Kinney, L.F. Bonewald, Glucocorticoid treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J. Bone Miner. Res. 21, 466\u2013476 (2006)","journal-title":"J. Bone Miner. Res."},{"key":"1146_CR9","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Staa Van","year":"2003","unstructured":"T.P. Van Staa, R.F. Laan, I.P. Barton, S. Cohen, D.M. Reid DM, C. Cooper, Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48, 3224\u20133229 (2003)","journal-title":"Arthritis Rheum."},{"key":"1146_CR10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrendo.2013.5","volume":"9","author":"G Mazziotti","year":"2013","unstructured":"G. Mazziotti, A. Giustina, Glucocorticoids and the regulation of growth hormone secretion. Nat. Rev. Endocrinol 9, 265\u2013276 (2013)","journal-title":"Nat. Rev. Endocrinol"},{"key":"1146_CR11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1385\/ENDO:11:2:151","volume":"11","author":"CE Dean","year":"1999","unstructured":"C.E. Dean, B. Morpurgo, T.E. Porter, Induction of somatotroph differentiation in vivo by corticosterone administration during chicken embryonic development. Endocrine 11, 151\u2013156 (1999)","journal-title":"Endocrine"},{"key":"1146_CR12","first-page":"717","volume":"19","author":"A Giustina","year":"1998","unstructured":"A. Giustina, J.D. Veldhuis, Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 19, 717\u2013797 (1998)","journal-title":"Endocr. Rev."},{"key":"1146_CR13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2826.1996.04779.x","volume":"8","author":"A Tamaki","year":"1996","unstructured":"A. Tamaki, M. Sato, S. Matsubara, Y. Wada, J. Takahara, Dexamethasone increases growth hormone (GH)-releasing hormone (GHR) receptor mRNA levels in culture rat anterior pituitary cells. Neuroendocrinology 8, 475\u2013480 (1996)","journal-title":"Neuroendocrinology"},{"key":"1146_CR14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1210\/jcem-68-1-120","volume":"68","author":"A Giustina","year":"1989","unstructured":"A. Giustina, G. Romanelli, R. Candrina, G. Giustina, Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid replacement. J. Clin. Endocrinol. Metab. 68, 120\u2013124 (1989)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12020-014-0257-3","volume":"47","author":"Y Hattori","year":"2014","unstructured":"Y. Hattori, T. Takeda, M. Fujii, J. Taura, Y. Ishii, H. Yamada, Dioxin-induced fetal growth retardation: the role of a preceding attenuation in the circulating level of glucocorticoid. Endocrine 47, 572\u2013580 (2014)","journal-title":"Endocrine"},{"key":"1146_CR16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12020-014-0278-y","volume":"47","author":"A Giustina","year":"2014","unstructured":"A. Giustina, G. Mazziotti, Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect. Endocrine 47, 354\u2013356 (2014)","journal-title":"Endocrine"},{"key":"1146_CR17","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1210\/endo-127-6-2705","volume":"127","author":"WB Wehrenberg","year":"1990","unstructured":"W.B. Wehrenberg, P.J. Bergman, L. Stagg, J. Ndon, A. Giustina, Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. Endocrinology 127, 2705\u20132708 (1990)","journal-title":"Endocrinology"},{"key":"1146_CR18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1210\/endo.143.4.8716","volume":"143","author":"G Tulipano","year":"2002","unstructured":"G. Tulipano, D. Soldi, M. Bagnasco, M.D. Culler, J.E. Taylor, D. Cocchi, A. Giustina, Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143, 1218\u20131224 (2002)","journal-title":"Endocrinology"},{"key":"1146_CR19","first-page":"1301","volume":"74","author":"A Giustina","year":"1992","unstructured":"A. Giustina, S. Bossoni, C. Bodini, A. Girelli, G.P. Balestrieri, G. Pizzocolo, W.B. Wehrenberg, Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy. J. Clin. Endocrinol. Metab. 74, 1301\u20131305 (1992)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1530\/acta.0.1220206","volume":"122","author":"A Giustina","year":"1990","unstructured":"A. Giustina, M. Doga, C. Bodini, A. Girelli, F. Legati, S. Bossoni, G. Romanelli, Acute effects of cortisone acetate on growth hormone response to growth hormone-releasing hormone in normal adult subjects. Acta Endocrinol. 122, 206\u2013210 (1990)","journal-title":"Acta Endocrinol."},{"key":"1146_CR21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1378\/chest.127.2.515","volume":"127","author":"M Malerba","year":"2005","unstructured":"M. Malerba, S. Bossoni, A. Radaeli, E. Mori, S. Bonadonna, A. Giustina, C. Tantucci, Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment. Chest 127, 515\u2013521 (2005)","journal-title":"Chest"},{"key":"1146_CR22","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1210\/jcem.85.3.6531","volume":"85","author":"M Terzolo","year":"2000","unstructured":"M. Terzolo, S. Bossoni, A. Al\u0131, M. Doga, G. Reimondo, G. Milani, P. Peretti, F. Manelli, A. Angeli, A. Giustina, Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone. J. Clin. Endocrinol. Metab. 85, 1310\u20131315 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR23","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1159\/000064764","volume":"58","author":"Z Hochberg","year":"2002","unstructured":"Z. Hochberg, Mechanisms of steroid impairment of growth. Horm. Res. 58, S33\u2013S38 (2002)","journal-title":"Horm. Res."},{"key":"1146_CR24","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1530\/EJE-09-0319","volume":"161","author":"H Filipsson","year":"2009","unstructured":"H. Filipsson, G. Johannsson, GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur. J. Endocrinol. 161, S85\u2013S95 (2009)","journal-title":"Eur. J. Endocrinol."},{"key":"1146_CR25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2007-0036","volume":"29","author":"A Giustina","year":"2008","unstructured":"A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535\u2013559 (2008)","journal-title":"Endocr. Rev."},{"key":"1146_CR26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","volume":"39","author":"A Angeli","year":"2006","unstructured":"A. Angeli, G. Guglielmi, A. Dovio, G. Capelli, D. de Feo, S. Giannini, R. Giorgino, L. Moro, A. Giustina, High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39, 253\u2013259 (2006)","journal-title":"Bone"},{"key":"1146_CR27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12020-015-0738-z","volume":"52","author":"G Mazziotti","year":"2016","unstructured":"G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni, T. Porcelli, L. Cerri, R. Maroldi, A. Giustina, Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52, 103\u2013110 (2016)","journal-title":"Endocrine"},{"key":"1146_CR28","first-page":"122","volume":"80","author":"A Giustina","year":"1995","unstructured":"A. Giustina, A.R. Bussi, C. Jacobello, W.B. Wehrenberg, Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J. Clin. Endocrinol. Metab. 80, 122\u2013129 (1995)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1172\/JCI114694","volume":"86","author":"FF Horber","year":"1990","unstructured":"F.F. Horber, M.W. Haymond, Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J. Clin. Invest. 86, 265\u2013272 (1990)","journal-title":"J. Clin. Invest."},{"key":"1146_CR30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03343985","volume":"25","author":"MA Magiakou","year":"2002","unstructured":"M.A. Magiakou, G.P. Chrousos GP, Cushing\u2019s syndrome in children and adolescents: current diagnostic and therapeutic strategies. J. Endocrinol. Invest. 25, 181\u2013194 (2002)","journal-title":"J. Endocrinol. Invest."},{"key":"1146_CR31","first-page":"318","volume":"47","author":"RG McArthur","year":"1972","unstructured":"R.G. McArthur, M.D. Cloutier, A.B. Hayles, R.G. Sprague, Cushing\u2019s disease in children. Findings in 13 cases. Mayo. Clin. Proc. 47, 318\u2013326 (1972)","journal-title":"Mayo. Clin. Proc."},{"key":"1146_CR32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1542\/peds.56.5.797","volume":"56","author":"DH Streeten","year":"1975","unstructured":"D.H. Streeten, F.H. Faas, M.J. Elders, T.G. Dalakos, M. Voorhess, Hypercortisolism in childhood: shortcomings of conventional diagnostic criteria. Pediatrics 56, 797\u2013803 (1975)","journal-title":"Pediatrics"},{"key":"1146_CR33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/00000658-198405000-00008","volume":"199","author":"CG Thomas Jr.","year":"1984","unstructured":"C.G. Thomas Jr., A.T. Smith, J.M. Griffith, F.B. Askin, Hyperadrenalism in childhood and adolescence. Ann. Surg. 199, 538\u2013548 (1984)","journal-title":"Ann. Surg."},{"key":"1146_CR34","first-page":"1082","volume":"79","author":"MA Magiakou","year":"1994","unstructured":"M.A. Magiakou, G. Mastorakos, G.P. Chrousos, Final stature in patients with endogenous Cushing\u2019s syndrome. J. Clin. Endocrinol. Metab. 79, 1082\u20131085 (1994)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.1365-2265.1999.00738.x","volume":"51","author":"NR Hughes","year":"1999","unstructured":"N.R. Hughes, C.A. Lissett, S.M. Shalet, Growth hormone status following treatment for Cushing\u2019s syndrome. Clin. Endocrinol. (Oxf). 51, 61\u201366 (1999)","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"1146_CR36","first-page":"131","volume":"78","author":"MA Magiakou","year":"1994","unstructured":"M.A. Magiakou, G. Mastorakos, M.T. Gomez, S.R. Rose, G.P. Chrousos, Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing\u2019s disease before and after surgical cure. J. Clin. Endocrinol. Metab. 78, 131\u2013137 (1994)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl 1","key":"1146_CR37","first-page":"24","volume":"55","author":"MO Savage","year":"2001","unstructured":"M.O. Savage, A. Lienhardt, M.C. Lebrethon, L.B. Johnston, A. Huebner, A.B. Grossman, F. Afshar, P.N. Plowman, G.M. Besser, Cushing\u2019s disease in childhood: presentation, investigation, treatment and long-term outcome. Horm. Res. 55(Suppl 1), 24\u201330 (2001)","journal-title":"Horm. Res."},{"key":"1146_CR38","first-page":"3262","volume":"85","author":"MC Lebrethon","year":"2000","unstructured":"M.C. Lebrethon, A.B. Grossman, F. Afshar, P.N. Plowman, G.M. Besser, M.O. Savage, Linear growth and final height after treatment for Cushing\u2019s disease in childhood. J. Clin. Endocrinol. Metab. 85, 3262\u20133265 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1530\/EJE-06-0588","volume":"156","author":"LF Chan","year":"2007","unstructured":"L.F. Chan, H.L. Storr, P.N. Plowman, L.A. Perry, G.M. Besser, A.B. Grossman, M.O. Savage, Long-term anterior pituitary function in patients with paediatric Cushing\u2019s disease treated with pituitary radiotherapy. Eur. J. Endocrinol. 156, 477\u2013482 (2007)","journal-title":"Eur. J. Endocrinol."},{"key":"1146_CR40","first-page":"341","volume":"67","author":"V Khanine","year":"2000","unstructured":"V. Khanine, J.J. Fournier, E. Requeda, J.P. Luton, F. Simon, J. Crouzet, Osteoporotic fractures at presentation of Cushing\u2019s disease: two case reports and a literature review. Joint Bone Spine 67, 341\u2013345 (2000)","journal-title":"Joint Bone Spine"},{"key":"1146_CR41","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00198-007-0514-x","volume":"19","author":"L Futo","year":"2008","unstructured":"L. Futo, J. Toke, A. Patocs, A. Szappanos, I. Varga, E. Glaz, Z. Tulassay, K. Racz, M. Toth, Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing\u2019s syndrome. Osteoporos. Int. 19, 941\u2013949 (2008)","journal-title":"Osteoporos. Int."},{"key":"1146_CR42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1530\/eje.0.1410126","volume":"141","author":"K Godang","year":"1999","unstructured":"K. Godang, T. Ueland, J. Bollerslev, Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing\u2019s syndrome. Eur. J. Endocrinol. 141, 126\u2013131 (1999)","journal-title":"Eur. J. Endocrinol."},{"key":"1146_CR43","first-page":"2859","volume":"80","author":"AR Hermus","year":"1995","unstructured":"A.R. Hermus, A.G. Smals, L.M. Swinkels, D.A. Huysmans, G.F. Pieters, C.F. Sweep, F.H. Corstens, P.W. Kloppenborg PW, Bone mineral density and bone turnover before and after surgical cure of Cushing\u2019s syndrome. J. Clin. Endocrinol. Metab. 80, 2859\u20132865 (1995)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s00268-007-9394-7","volume":"32","author":"A Kawamata","year":"2008","unstructured":"A. Kawamata, M. Iihara, T. Okamoto, T. Obara, Bone mineral density before and after surgical cure of Cushing\u2019s syndrome due to adrenocortical adenoma: prospective study. World J. Surg. 32, 890\u2013896 (2008)","journal-title":"World J. Surg."},{"key":"1146_CR45","first-page":"137","volume":"65","author":"AW Eerden van der","year":"2007","unstructured":"A.W. van der Eerden, M. den Heijer, W.J. Oyen, A.R. Hermus, Cushing\u2019s syndrome and bone mineral density: lowest Z scores in young patients. Neth. J. Med. 65, 137\u2013141 (2007)","journal-title":"Neth. J. Med."},{"key":"1146_CR46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.0300-0664.2001.01454.doc.x","volume":"56","author":"C Somma Di","year":"2002","unstructured":"C. Di Somma, R. Pivonello, S. Loche, A. Faggiano, P. Marzullo, A. Di Sarno, M. Klain, M. Salvatore, G. Lombardi, A. Colao, Severe impairment of bone mass and turnover in Cushing\u2019s disease: comparison between childhood-onset and adulthood-onset disease. Clin. Endocrinol. 56, 153\u2013158 (2002)","journal-title":"Clin. Endocrinol."},{"key":"1146_CR47","first-page":"3196","volume":"82","author":"DJ Devoe","year":"1997","unstructured":"D.J. Devoe, W.L. Miller, F.A. Conte, S.L. Kaplan, M.M. Grumbach, S.M. Rosenthal, C.B. Wilson, S.E. Gitelman, Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing\u2019s disease. J. Clin. Endocrinol. Metab. 82, 3196\u20133202 (1997)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR48","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2265.2003.01713.x","volume":"58","author":"C Somma Di","year":"2003","unstructured":"C. Di Somma, R. Pivonello, S. Loche, A. Faggiano, M. Klain, M. Salvatore, G. Lombardi, A. Colao, Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing\u2019s disease: a prospective study. Clin. Endocrinol. 58, 302\u2013308 (2003)","journal-title":"Clin. Endocrinol."},{"key":"1146_CR49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.6065\/apem.2014.19.3.164","volume":"19","author":"I Jeong","year":"2014","unstructured":"I. Jeong, M. Oh, J.H. Kim, J.H. Cho, J.H. Choi, H.W. Yoo, Long-term follow-up on Cushing disease patient after transsphenoidal surgery. Ann. Pediatr. Endocrinol. Metab. 19, 164\u2013168 (2014)","journal-title":"Ann. Pediatr. Endocrinol. Metab."},{"key":"1146_CR50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF03345378","volume":"28","author":"S Scommegna","year":"2005","unstructured":"S. Scommegna, J.P. Greening, H.L. Storr, K.M. Davies, N.J. Shaw, J.P. Monson, A.B. Grossman, M.O. Savage, Bone mineral density at diagnosis and following successful treatment of pediatric Cushing\u2019s disease. J. Endocrinol. Invest. 28, 231\u2013235 (2005)","journal-title":"J. Endocrinol. Invest."},{"key":"1146_CR51","first-page":"1905","volume":"81","author":"GM Leong","year":"1996","unstructured":"G.M. Leong, L.B. Mercado-Asis, J.C. Reynolds, S.C. Hill, E.H. Oldfield, G.P. Chrousos, : The effect of Cushing\u2019s disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair. J. Clin. Endocrinol. Metab. 81, 1905\u20131911 (1996)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1359\/jbmr.061010","volume":"22","author":"GM Leong","year":"2007","unstructured":"G.M. Leong, V. Abad, E. Charmandari, J.C. Reynolds, S. Hill, G.P. Chrousos, L.K. Nieman, Effects of child- and adolescent-onset endogenous cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J. Bone Miner. Res. 22, 110\u2013118 (2007)","journal-title":"J. Bone Miner. Res."},{"key":"1146_CR53","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jpeds.2009.12.027","volume":"156","author":"MB Lodish","year":"2010","unstructured":"M.B. Lodish, H.P. Hsiao, A. Serbis, N. Sinaii, A. Rothenbuhler, M.F. Keil, S.A. Boikos, J.C. Reynolds, C.A. Stratakis, Effects of Cushing disease on bone mineral density in a pediatric population. J. Pediatr. 156, 1001\u20131005 (2010)","journal-title":"J. Pediatr."},{"key":"1146_CR54","doi-asserted-by":"crossref","first-page":"14544","DOI":"10.1074\/jbc.M112.427054","volume":"288","author":"Y Zhang","year":"2013","unstructured":"Y. Zhang, D.Y.M. Leung, E. Goleva, Vitamin D enhances glucocorticoid action in human monocytes. J. Biol. Chem. 288, 14544\u201314553 (2013)","journal-title":"J. Biol. Chem."},{"key":"1146_CR55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaci.2012.04.005","volume":"130","author":"SM Tse","year":"2012","unstructured":"S.M. Tse, H.W. Kelly, A.A. Litonjua, M.L. Van Natta, S.T. Weiss, K.G. Tantisira; Childhood Asthma Management Program Research Group, Corticosteroid use and bone mineral accretion in children with asthma: effect modification by vitamin D. J. Allergy Clin. Immunol. 130, 53\u201360 (2012)","journal-title":"J. Allergy Clin. Immunol."},{"key":"1146_CR56","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1210\/jc.2011-2757","volume":"97","author":"ZE Davidson","year":"2012","unstructured":"Z.E. Davidson, K.Z. Walker, H. Truby, Do glucocorticoids alter vitamin D status? A systematic review with meta-analyses of observational studies. J. Clin. Endocrinol. Metab. 97, 738\u2013744 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR57","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/EJE-13-0435","volume":"169","author":"E Romagnoli","year":"2013","unstructured":"E. Romagnoli, J. Pepe, S. Piemonte, C. Cipriani, S. Minisola, Management of endocrine disease: value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. Eur. J. Endocrinol. 169, R59\u2013R69 (2013)","journal-title":"Eur. J. Endocrinol."},{"key":"1146_CR58","doi-asserted-by":"crossref","first-page":"841248","DOI":"10.1155\/2014\/841248","volume":"2014","author":"C Cipriani","year":"2014","unstructured":"C. Cipriani, J. Pepe, S. Piemonte, L. Colangelo, M. Cilli, S. Minisola, Vitamin d and its relationship with obesity and muscle. Int. J. Endocrinol. 2014, 841248 (2014)","journal-title":"Int. J. Endocrinol."},{"key":"1146_CR59","doi-asserted-by":"crossref","first-page":"G92","DOI":"10.1152\/ajpgi.00317.2006","volume":"292","author":"S Huybers","year":"2007","unstructured":"S. Huybers, T.H. Naber, R.J. Bindels, J.G. Hoenderop, Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G92\u2013G97 (2007)","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1146_CR60","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00198-004-1757-4","volume":"16","author":"J Pepe","year":"2005","unstructured":"J. Pepe, E. Romagnoli, I. Nofroni, M.T. Pacitti, S. De Geronimo, C. Letizia, G.,G. Tonnarini, A. Scarpiello, E. D\u2019Erasmo, S. Minisola, Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos. Int. 16, 805\u2013812 (2005)","journal-title":"Osteoporos. Int."},{"key":"1146_CR61","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/jbmr.5650101114","volume":"10","author":"E Paz-Pacheco","year":"1995","unstructured":"E. Paz-Pacheco, G. El-Hajj Fuleihan, M. Leboff, Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J. Bone Miner. Res. 10, 1713\u20131718 (1995)","journal-title":"J. Bone Miner. Res."},{"key":"1146_CR62","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1530\/eje.1.01841","volume":"152","author":"S Bonadonna","year":"2005","unstructured":"S. Bonadonna, A. Burattin, M. Nuzzo, G. Bugari, E. Agabiti-Rosei, D. Valle, N. Iori, J.P. Bilezikian, J.D. Veldhuis, A. Giustina, Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur. J. Endocrinol. 152, 199\u2013205 (2005)","journal-title":"Eur. J. Endocrinol."},{"key":"1146_CR63","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/jbmr.362","volume":"26","author":"KE Hansen","year":"2011","unstructured":"K.E. Hansen, H.A. Wilson, C. Zapalowski, H.A. Fink, S. Minisola, R.A. Adler, Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J. Bone Miner. Res. 26, 1989\u201396 (2011)","journal-title":"J. Bone Miner. Res."},{"key":"1146_CR64","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"J.M. Grossman, R. Gordon, V.K. Ranganath, C. Deal, L. Caplan, W. Chen, J.R. Curtis, D.E. Furst, M. McMahon, N.M. Patkar, E. Volkmann, K.G. Saag, American college of rheumatology recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Care Res. 62, 1515\u20131526 (2010)","journal-title":"Arthritis Care Res."},{"key":"1146_CR65","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"S Lekamwasam","year":"2012","unstructured":"S. Lekamwasam, J.D. Adachi, D. Agnusdei, J.P. Bilezikian, S. Boonen, F. Borgstr\u00f6m, C. Cooper, A. Diez Perez, R. Eastell, L.C. Hofbauer, J.A. Kanis, B.L. Langdahl, O. Lesnyak, R. Lorenc, E. McCloskey, O.D. Messina, N. Napoli, B. Obermayer-Pietsch, S.H. Ralston, P.N. Sambrook, S. Silverman, M. Sosa, J. Stepan, G. Suppan, D.A. Wahl, J.E. Compston; Joint IOF-ECTS GIO Guidelines Working Group, A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporosis Int. 23, 2257\u20132276 (2012)","journal-title":"Osteoporosis Int."},{"key":"1146_CR66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","volume":"96","author":"AC Ross","year":"2011","unstructured":"A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, S.A. Shapses, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96, 53\u201358 (2011)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1146_CR67","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jbmr.328","volume":"26","author":"RP Heaney","year":"2011","unstructured":"R.P. Heaney, M.F. Holick, Why the IOM recommendations for vitamin D are deficient. J. Bone Miner. Res. 26, 455\u2013457 (2011)","journal-title":"J. Bone Miner. Res."},{"key":"1146_CR68","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"K.G. Saag, R. Emkey, T.J. Schnitzer, J.P. Brown, F. Hawkins, S. Goemaere, G. Thamsborg, U.A. Liberman, P.D. Delmas, M.P. Malice, M. Czachur, A.G. Daifotis, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced osteoporosis intervention study group. N. Engl. J. Med. 339, 292\u2013299 (1998)","journal-title":"N. Engl. J. Med."},{"key":"1146_CR69","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"J.D. Adachi, K.G. Saag, P.D. Delmas, U.A. Liberman, R.D. Emkey, E. Seeman, N.E. Lane, J.M. Kaufman, P.E. Poubelle, F. Hawkins, R. Correa-Rotter, C.J. Menkes, J.A. Rodriguez-Portales, T.J. Schnitzer, J.A. Block, J. Wing, H.H. McIlwain, R. Westhovens, J. Brown, J.A. Melo-Gomes, B.L. Gruber, M.J. Yanover, M.O. Leite, K.G. Siminoski, M.C. Nevitt, J.T. Sharp, M.P. Malice, T. Dumortier, M. Czachur, W. Carofano, A. Daifotis, Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44, 202\u2013211 (2001)","journal-title":"Arthritis Rheum."},{"key":"1146_CR70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"S. Wallach, S. Cohen, D.M. Reid, R.A. Hughes, D.J. Hosking, R.F. Laan, S.M. Doherty, M. Maricic, C. Rosen, J. Brown, I. Barton, A.A. Chines, Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67, 277\u2013285 (2000)","journal-title":"Calcif. Tissue Int."},{"key":"1146_CR71","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"D.M. Reid, J.P. Devogelaer, K.G. Saag, C. Roux, C.S. Lau, J.Y. Reginster, P. Papanastasiou, A. Ferreira, F. Hartl, T. Fashola, P. Mesenbrink, P.N. Sambrook; HORIZON investigators, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373, 1253\u20131263 (2009)","journal-title":"Lancet"},{"key":"1146_CR72","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/13102818.2014.967827","volume":"28","author":"T Petranova","year":"2014","unstructured":"T. Petranova, I. Sheytanov, S. Monov, R. Nestorova, R. Rashkov, Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol. Biotechnol. Equip. 28, 1127\u20131137 (2014)","journal-title":"Biotechnol. Biotechnol. Equip."},{"key":"1146_CR73","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2015.03.002","volume":"75","author":"CC Mok","year":"2015","unstructured":"C.C. Mok, L.Y. Ho, K.M. Ma, Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone 75, 222\u2013228 (2015)","journal-title":"Bone"},{"key":"1146_CR74","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","volume":"75","author":"T Takeuchi","year":"2016","unstructured":"T. Takeuchi, Y. Tanaka, N. Ishiguro, H. Yamanaka, T. Yoneda, T. Ohira, N. Okubo, H.K. Genant, D. van der Heijde, Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with rheumatoId arthritis on methotrexate to validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann. Rheum. Dis. 75, 983\u2013990 (2016)","journal-title":"Ann. Rheum. Dis."},{"key":"1146_CR75","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(09)60704-2","volume":"373","author":"L Gennari","year":"2009","unstructured":"L. Gennari, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: hope on the HORIZON. Lancet 373, 1225\u20131226 (2009)","journal-title":"Lancet"},{"key":"1146_CR76","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"K.G. Saag, E. Shane, S. Boonen, F. Mar\u00edn, D.W. Donley, K.A. Taylor, G.P. Dalsky, R. Marcus, Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Eng. J. Med. 357, 2028\u20132039 (2007)","journal-title":"N. Eng. J. Med."},{"key":"1146_CR77","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"K.G. Saag, J.R. Zanchetta, J.P. Devogelaer, R.A. Adler, R. Eastell, K. See, J.H. Krege, K. Krohn, M.R. Warner, Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346\u20133355 (2009)","journal-title":"Arthritis Rheum."},{"key":"1146_CR78","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3899\/jrheum.090411","volume":"37","author":"JP Devogelaer","year":"2010","unstructured":"J.P. Devogelaer, R.A. Adler, C. Recknor, K. See, M.R. Warner, M. Wong, K. Krohn, Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J. Rheumatol. 37, 141\u2013148 (2010)","journal-title":"J. Rheumatol."},{"key":"1146_CR79","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","volume":"12","author":"BL Langdahl","year":"2009","unstructured":"B.L. Langdahl, F. Marin, E. Shane, H. Dobnig, J.R. Zanchetta, M. Maricic, K. Krohn, K. See, M.R. Warner, Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporosis Int. 12, 2095\u20132104 (2009)","journal-title":"Osteoporosis Int."},{"key":"1146_CR80","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jbmr.1870","volume":"28","author":"CC Gl\u00fcer","year":"2013","unstructured":"C.C. Gl\u00fcer, F. Marin, J.D. Ringe, F. Hawkins, R. M\u00f6ricke, N. Papaioannu, P. Farahmand, S. Minisola, G. Mart\u00ednez, J.M. Nolla, C. Niedhart, N. Gua\u00f1abens, R. Nuti, E. Mart\u00edn-Mola, F. Thomasius, G. Kapetanos, J. Pe\u00f1a, C. Graeff, H. Petto, B. Sanz, A. Reisinger, P.K. Zysset, Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J. Bone Miner. Res. 28, 1355\u20131368 (2013)","journal-title":"J. Bone Miner. Res."},{"key":"1146_CR81","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bone.2014.07.008","volume":"67","author":"G Mazziotti","year":"2014","unstructured":"G. Mazziotti, F. Maffezzoni, M. Doga, L.C. Hofbauer, R.A. Adler, A. Giustina, Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs. Bone 67, 175\u2013180 (2014)","journal-title":"Bone"},{"key":"1146_CR82","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jbspin.2014.10.001","volume":"81","author":"K Briot","year":"2014","unstructured":"K. Briot, B. Cortet, C. Roux, L. Fardet, V. Abitbol, J. Bacchetta, D. Buchon, F. Debiais, P. Guggenbuhl, M. Laroche, E. Legrand, E. Lespessalilles, C. Marcelli, G. Weryha, T. Thomas, Bone section of the french society for rheumatology (SFR) and osteoporosis research and information group (GRIO). Joint Bone Spine 81, 493\u2013501 (2014)","journal-title":"Joint Bone Spine"},{"key":"1146_CR83","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.semarthrit.2014.09.011","volume":"44","author":"HO Tory","year":"2015","unstructured":"H.O. Tory, D.H. Solomon, S.P. Desai, Analysis of quality improvement efforts in preventing glucocorticoid-induced osteoporosis. Sem. Arthritis Rheum. 44, 483\u2013488 (2015)","journal-title":"Sem. Arthritis Rheum."},{"key":"1146_CR84","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3899\/jrheum.141238","volume":"42","author":"AH Warriner","year":"2015","unstructured":"A.H. Warriner, R.C. Outman, J.J. Allison, J.R. Curtis, N.J. Markward, D.T. Redden, M.M. Safford, E.J. Stanek, A.R. Steinkellner, K.G. Saag, An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid users. J. Rheumatol. 42, 1478\u20131483 (2015)","journal-title":"J. Rheumatol."},{"key":"1146_CR85","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archinte.167.6.591","volume":"167","author":"JR Curtis","year":"2007","unstructured":"J.R. Curtis, A.O. Westfall, J. Allison, Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch. Intern. Med. 167, 591\u2013596 (2007)","journal-title":"Arch. Intern. Med."},{"key":"1146_CR86","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/art.20403","volume":"51","author":"DH Solomon","year":"2004","unstructured":"D.H. Solomon, J.N. Katz, J.P. Jacobs, A.M. La Tourette, J. Coblyn, Multifaceted intervention to improve rheumatologists\u2019 management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum. 51, 383\u2013387 (2004)","journal-title":"Arthritis Rheum."},{"key":"1146_CR87","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11606-013-2360-1","volume":"28","author":"MJ Kohler","year":"2013","unstructured":"M.J. Kohler, M. Amezaga, J. Drozd, S.T. Crowley, B. Gulanski, D.R. Anderson, L. Fraenkel, Use of a computerized order set to increase prescription of calcium and vitamin D supplementation in patients receiving glucocorticoids. J. Gen. Intern. Med. 28, 825\u2013829 (2013)","journal-title":"J. Gen. Intern. Med."},{"key":"1146_CR88","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00198-006-0149-3","volume":"17","author":"ED Newman","year":"2006","unstructured":"E.D. Newman, C.K. Matzko, T.P. Olenginski, J.L. Perruquet, T.M. Harrington, G. Maloney-Saxon, T. Culp, G.C. Wood, Glucocorticoid-induced osteoporosis program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at1 year. Osteoporos. Int. 17, 1428\u20131434 (2006)","journal-title":"Osteoporos. Int."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-1146-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-016-1146-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-016-1146-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T17:02:35Z","timestamp":1657472555000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-016-1146-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,20]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1146"],"URL":"https:\/\/doi.org\/10.1007\/s12020-016-1146-8","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,20]]}}}